Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Inflammation01:38

Inflammation

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in Cardiac-Arterial Coupling After Cardiac Surgery for Aortic Valve Disease.

Reviews in cardiovascular medicine·2026
Same author

Proresolving mediators as cardiovascular biomarkers: solo players or an orchestra?

European heart journal open·2026
Same author

Artificial Intelligence in Biomedical Scientific Publishing.

European heart journal·2026
Same author

Ferroptosis promotes aortic stenosis through 5-lipoxygenase.

European heart journal·2026
Same author

First quinquennium completed: highlights from <i>EHJ Open</i> 2025.

European heart journal open·2026
Same author

Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities.

European heart journal·2026

Related Experiment Video

Updated: Jun 13, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with &beta;-arrestin
13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

Leukotrienes and atherosclerosis.

Graziano Riccioni1, Magnus Bäck, Valérie Capra

  • 1Cardiology Unit, San Camillo de Lellis Hospital, Manfredonia, Foggia, Italy. griccioni@hotmail.com

Current Drug Targets
|April 15, 2010
PubMed
Summary

Leukotrienes (LT) play a role in atherosclerosis development and complications. Targeting LT pathways with antagonists shows promise for treating these vascular diseases.

Area of Science:

  • Biomedical Science
  • Cardiovascular Research
  • Inflammation Biology

Background:

  • Leukotrienes (LT) signaling is implicated in atherosclerosis pathogenesis.
  • LT biosynthetic enzymes and receptors are present in atherosclerotic lesions.
  • Genetic studies link LT pathway variants to acute myocardial infarction (AMI) and stroke risk.

Purpose of the Study:

  • To review the role of leukotrienes and their receptors in atherosclerosis.
  • To summarize current understanding of LT involvement in vascular disease progression.
  • To discuss recent developments in anti-leukotriene therapies for ischemic complications.

Main Methods:

  • Review of experimental and genetic studies.
  • Analysis of literature on leukotriene biosynthesis and function in the vascular wall.

More Related Videos

Flow Cytometry Analysis of Immune Cells Within Murine Aortas
15:15

Flow Cytometry Analysis of Immune Cells Within Murine Aortas

Published on: July 1, 2011

Related Experiment Videos

Last Updated: Jun 13, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with &beta;-arrestin
13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

Flow Cytometry Analysis of Immune Cells Within Murine Aortas
15:15

Flow Cytometry Analysis of Immune Cells Within Murine Aortas

Published on: July 1, 2011

  • Examination of clinical data regarding LT pathway gene variants.
  • Assessment of anti-leukotriene therapeutic strategies.

    • Main Results:

    • Leukotrienes (Cys-LTs, LTB4) promote inflammation via CysLT and BLT receptors on vascular cells.
    • Genetic variations in the 5-lipoxygenase (5-LO) pathway correlate with AMI and stroke risk.
    • Anti-leukotriene agents are being re-evaluated for atherosclerosis treatment.

    Conclusions:

    • Leukotriene signaling is a key factor in atherosclerosis and its ischemic consequences.
    • Targeting leukotriene pathways offers a potential therapeutic approach for cardiovascular diseases.
    • Further research into LT antagonists is warranted for managing atherosclerosis and related conditions.